# OnCo record nct04975997 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04975997/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04975997", "NCT04975997" ;
  schema:name "Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants "@en ;
  schema:alternateName "EXCALIBER-RRMM"@en ;
  schema:description "A phase 3 trial of Dexamethasone, Daratumumab, Bortezomib in multiple myeloma, run by Celgene, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04975997/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04975997> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-06-23" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/antiemetic-therapy/>, <https://onco.cc/technologies/celmods/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:drugs <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/iberdomide/> ;
  onco:companies <https://onco.cc/companies/bms/> .